Please assess the completion status of the following clinical trial:

Trial Title: Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion for Matched Control Subjects:~* Undergone normal growth and development~* Normal serum prolactin (PRL) concentrations~* Females should have a history of regular, age-appropriate menses~* Males should have normal serum testosterone concentrations~* Matched GHD subject already enrolled in study; matched in terms of sex, age, BMI and Estrogen status (women only)~Exclusion Criteria for Matched Control Subjects:~* Inability or unwillingness to comply with study medication~* Pregnancy or lactation~* Clinically relevant ECG abnormalities (including QT/QTc interval \> 450 ms) at any time prior to dosing at Visit 2~* Treatment with any drugs that might prolong QT/QTc~Inclusion criteria dor Adult GHD Subjects:~* Confirmed GH deficiency with a low IGF-1~* 3 months of stable treatment for those requiring hormone replacement therapy for hormones deficiencies other than GHD~* subjects with hypogonadism must be treated with sex steroid therapy, excluding women over 50 yr of age~* women on estrogen therapy, for whatever reason, must be on stable treatment for ar least 3 months prior to study~Exclusion criteria for Adult GHD Subjects:~* Untreated hypothyroidism~* Known hypersensitivity to any excipient in study medication~* Inability or unwillingness to comply with study procedures~* Intracranial lesions stable for less than 12 months~* GH therapy within one month of study entry~* Clinically significant cardiovascular, or cerebrovascular disease~* Current active malignancy other than non-melanoma skin cancer~* Renal or hepatic dysfunction (\> 3 x ULN liver function enzymes (LFEs) - aspartate amino transferase (ASAT); alanine amino transferase (ALAT); gamma-glutamyltransferase (GGT) or creatinine \> 2x ULN)~* Pregnancy or lactation~* Active Cushing's disease~* Clinically relevant ECG abnormalities (including QT/heart rate corrected QT interval (QTc) interval \> 450 ms) at any time prior to dosing at Visit 2~* Treatment with any drugs that might prolong QT/QTc

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AEZS-130 ( formerly ARD-07) (Type: EXPERIMENTAL): A single oral administration of AEZS-130 (0.5 mg/kg po) as Growth Hormone Stimulation Test
- L-ARG+GHRH (Type: ACTIVE_COMPARATOR): This trial was set up as a multi-center, randomized, cross-over study investigating AEZS-130 as a Growth Hormone Stimulation Tests in terms of safety and efficacy compared to L-ARG+GHRH. When GHRH became unavailable on the US market, this comparator arm was no longer available, which was addressed by Amendment No. 3 (version 27-March-2010). Control subject enrolled under Amendment No. 3 were not randomized as there was no cross-over due to unavailability of L-ARG+GHRH. These control subjects received only AEZS-130

Based on this trial design, predict the completion outcome and termination type (if applicable).